• John Miller
• 10 Apr, 2020

ZURICH (Reuters) - Drugs being re-purposed in hopes they will help against COVID-19 cost little to make but may prove challenging to produce in quantities needed for a pandemic, a drug pricing expert said. “Any pharmaceutical company manufacturing any treatment currently in clinical trials against coronavirus needs a clear plan to upscale production massively,” Andrew Hill, a University of Liverpool research fellow, told Reuters.
Read more...